Oruka Therapeutics, Inc. earnings releases ORKA

Oruka Therapeutics, Inc. last reported quarterly results on Aug 10, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026). It usually reports 25–41 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 2, 2026.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 25–41 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Aug 10, 2026
41 days after quarter end
Q2 FY2026
ended Jun 30, 2026
—
-41
-67.7%
—
Apr 30, 2026
30 days after quarter end
Q1 FY2026
ended Mar 31, 2026
—
-32
-51.5%
—
Aug 1, 2024
32 days after quarter end
—
ended Jun 30, 2024
—
—
—
Apr 25, 2024
25 days after quarter end
—
ended Mar 31, 2024
—
—
—
Feb 1, 2024
32 days after quarter end
—
ended Dec 31, 2023
—
—
—
Oct 18, 2023
18 days after quarter end
—
ended Sep 30, 2023
—
—
—
Jul 21, 2023
21 days after quarter end
—
ended Jun 30, 2023
—
—
—
Apr 24, 2023
24 days after quarter end
—
ended Mar 31, 2023
—
—
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ORKA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Menlo Park, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
907654
Former names
ARCA biopharma, Inc. (until Aug 30, 2024); NUVELO INC (until Jan 27, 2009); HYSEQ INC (until Jan 28, 2003)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.